Nadolol


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Cardiac arrhythmias, Prophylaxis of migraine
Adult: 40-160 mg once daily.

Oral
Angina pectoris
Adult: Initially, 40 mg once daily, increased wkly up to 160 mg/day depending on response. Max: 240 mg/day.

Oral
Adjunct in hyperthyroidism
Adult: 80-160 mg once daily. May require higher doses depending on patient's response.

Oral
Hypertension
Adult: Initially, 40-80 mg once daily, increased wkly to ≥240 mg/day according to response.
Elderly: Initially, 20 mg/day. Titrate according to response.
Renal Impairment
HTN, Angina pectoris:
May require lower dose or less frequent admin.
CrCl Dosage
<10 Given every 40-60 hr.
10-30 Given every 24-48 hr.
31-50 Given every 24-36 hr.
Cách dùng
May be taken with or without food.
Chống chỉ định
AV block (2nd and 3rd degree), sinus bradycardia, bronchial asthma, cardiogenic shock, or overt cardiac failure.
Thận trọng
Inadequate cardiac function, latent cardiac insufficiency, well-compensated heart failure, nonallergic bronchospasm, DM, myasthenia gravis, peripheral vascular disease including Raynaud's disease. Patients undergoing surgery involving general anaesth. Renal or hepatic impairment. May mask signs and symptoms of hyperthyroidism and acute hypoglycaemia. Avoid abrupt withdrawal as it may precipitate thyroid storm, exacerbate angina, HTN and MI. Pregnancy and lactation.
Phản ứng phụ
Dizziness, fatigue, hallucinations, mental depression, sedation, headache, paraesthesia, malaise, insomnia, sleep disturbances. Bradycardia, peripheral vascular insufficiency, GI disturbances (e.g. diarrhoea, nausea, vomiting). Bronchospasm, rash, pruritus, reversible alopecia, slurred speech, dry mouth, eyes and skin, facial swelling, wt gain, impotence, nasal stuffiness, tinnitus, cough, blurred vision, weakness, sweating, numbness and atypical behaviour.
MonitoringParameters
Monitor heart rate and BP. Carefully monitor signs/symptoms of angina exacerbation when discontinuing therapy.
Quá liều
Symptoms: Hypotension, bradycardia, bronchospasm, acute cardiac failure. Management: If ingestion is recent, emesis should be induced. Endotracheal intubation followed by gastric lavage w/ activated charcoal should be performed if patient is comatose, having seizures or lacks gag reflex. IV atropine sulfate may be given for excessive bradycardia, and if it persists, IV isoproterenol HCl may be administered cautiously. For hypotension, a vasopressor (e.g. dobutamine, dopamine, epinephrine, norepinephrine) may be given cautiously, and for bronchospasm, a β2-adrenergic agonist and/or IV aminophylline. An IV cardiac glycoside and diuretic may be used for cardiac failure. IV glucagon may also be useful. Haemodialysis may be beneficial in severe cases.
Tương tác
Antagonises β-adrenergic stimulating effects of sympathomimetic agents (e.g. isoproterenol). Additive hypotensive effects w/ diuretics or other hypotensive drugs, phenothiazines, reserpine. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. May potentiate and prolong the effects of neuromuscular blockers (e.g. tubocurarine Cl). Reduced antihypertensive effects w/ NSAIDs.
Tác dụng
Description: Nadolol is a non-cardioselective β-blocker. It lacks intrinsic sympathomimetic and membrane-stabilising activity.
Duration: 17-24 hr.
Pharmacokinetics:
Absorption: Incompletely absorbed from the GI tract. Time to peak plasma concentration: Approx 3 or 4 hr.
Distribution: Widely distributed and enters breast milk. Volume of distribution: Approx 2 L/kg. Plasma protein binding: Approx 30%.
Metabolism: Not metabolised.
Excretion: Via urine (as unchanged drug). Plasma half-life: Approx 12-24 hr.
Bảo quản
Store between 15-30°C. Avoid excessive heat. Protect from light.
Phân loại MIMS
References
Anon. Nadolol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 26/11/2013.

Buckingham R (ed). Nadolol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 26/11/2013.

Corgard Tablets. U.S. FDA. https://www.fda.gov/. Accessed 26/11/2013.

McEvoy GK, Snow EK, Miller J et al (eds). Nadolol. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 26/11/2013.

Wickersham RM. Nadolol. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. https://www.wolterskluwercdi.com/facts-comparisons-online/. Accessed 26/11/2013.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Nadolol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Apo-Nadol
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in